Market Overview

InfuSystem Ends Strategic Alternatives Assessment, Says Interim CEO to Step Down at End of Search

Related INFU
Meson Offers to Acquire InfuSystem for $1.85-$2.00/Share
Earnings Scheduled For May 13, 2013

The Board of Directors of InfuSystem Holdings, Inc. (NYSE: INFU) (“InfuSystem” or the “Company”), the leading national provider of infusion pumps and related services for the U.S. healthcare industry, has formally ended its assessment of potential strategic alternatives initiated by InfuSystem's prior management in conjunction with the investment banking firm, Houlihan Lokey. The Board stated that it believes the Company's current strategic plan offers greater value.

Making the announcement, Executive Chairman Ryan Morris said the Board unanimously agreed that, given current business indicators and the certainty stemming from the Company's recent financing arrangement, InfuSystem shareholders would be best served by remaining an independent public company. “The Company,” he added, “intends to focus on delivering consistent growth and profitable results in its core business as well as executing strategic initiatives designed to leverage its existing, strong client base.”

The Company anticipates that final costs associated with the strategic alternatives program its Board evaluated will be reflected in the fourth quarter 2012 results.

The Company also announced it has initiated a search process to hire a permanent Chief Executive Officer. The Board's Executive Search Committee, headed by Lead Independent Director John Climaco, will work closely with RobinsonButler, a top-tier retained executive search firm serving the life science industry, to conduct a thorough, transparent and expeditious search process. Interim CEO Dilip Singh will step down upon completion of the search assignment.

Posted-In: News Management

 

Related Articles (INFU)

Around the Web, We're Loving...

Get Benzinga's Newsletters